TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05989165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil 5% Topical Solution
Description: Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microneedling
Description: Patient will be given microneedling treatment every 4 weeks
Study: NCT05092425

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05922163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evidence-based VR simulation
Description: Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
Study: NCT06119529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3872386
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3872386
Description: Administered either IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered either IV or SC.
Study: NCT06444698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cookies that contain 50 grams of quinoa
Description: 250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cookies without quinoa
Description: The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.
Study: NCT05548907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep restriction treatment
Description: Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sleep diary monitoring
Description: As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
Study: NCT04521803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose Rifampicin (RIF)
Description: Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
Study: NCT05764330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo IF intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Undergo fasting
Study: NCT05686525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Microwave Thermotherapy
Description: TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolisation
Description: In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
Study: NCT05904587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureSmile® VPro™
Description: the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ortho technology, sports advantage, thermal forming soft EVA 3mm
Description: the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cotton roll
Description: the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
Study: NCT04549272

Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study: NCT05992220

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
Description: The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab plus bevacizumab
Description: Atezolizumab plus bevacizumab q3w
Study: NCT05676437

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography
Description: Radiographic examination during clinical stress test of knee laxity

Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography
Description: Radiographic examination during clinical stress test of knee laxity
Study: NCT05546489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymfit intervention
Description: Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
Study: NCT06291363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Hydrochloride
Description: Patients in the experimental group will receive esmolol during general anesthesia
Study: NCT04796987

Intervention type: DIAGNOSTIC_TEST
Intervention: Convolutional Neural Network
Description: Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.

Intervention type: DIAGNOSTIC_TEST
Intervention: Convolutional Neural Network
Description: Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
Study: NCT05551247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d3,Q3W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin (endostatin)
Description: 210mg,civ,d1-3,Q3W
Study: NCT04738318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
Study: NCT06551623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Oral Solution 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets 0.5 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 Capsules 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 Capsules 400 mg
Study: NCT06456593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obefazimod
Description: Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obefazimod
Description: Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obefazimod
Description: Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
Study: NCT05218772

Intervention type: OTHER
Intervention: Questionnaires
Description: Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)
Study: NCT06291363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in the standard of care group will receive saline as placebo during general anesthesia
Study: NCT04852393

Intervention type: PROCEDURE
Intervention: Block
Description: cervical medial branch block
Study: NCT01517321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0431/ONO-5435
Description: Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
Study: NCT05893641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A regular training volume
Description: Participate will maintain their training volume of 35 h/week
Study: NCT01517321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, MK-0431/ONO-5435
Description: Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
Study: NCT06311396

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic model
Description: Create a complete molecular-level description of the heterogeneous population of cells that are capable of giving rise to tumor transformation in the liver.
Study: NCT05893641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A lower exercise volume group
Description: Participate will conduct 85% of the control group weekly training volume (i.e., 30h/week)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A longer rest group
Description: Participate will maintain the 35 h/week of exercise training
Study: NCT04307563

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness session
Description: 1.5 hour weekly session with health educator
Study: NCT04928300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: low dose ketamine infusion 2.5 µ/kg/min for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: the same dose and duration of normal saline will be given for 5 days.
Study: NCT06279286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10506
Description: HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
Study: NCT06270615

Intervention type: OTHER
Intervention: Ambispective validation of machine learning-based predictive model
Description: Retrospective and prospective validation of a machine learning model to predict major haemorrhage in trauma patients compared to clinician prediction
Study: NCT06378970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio Book Application
Description: The Audio Book Application Preference Form asked about book preferences other than horror and thriller genres. The selected audiobook was played with headphones via tablet/smartphone. Separate headphones were used for each patient. Patient Follow-up Form and Facial Anxiety Scale evaluations; the initial measurement (M0) was evaluated before the intervention, the first measurement (M1) at the 15th minute of the intervention, the second measurement (M2) at the 30th minute of the intervention, and the third measurement (M3) 30 minutes after the end of the intervention. Care was taken to ensure that there was no deterioration in the comfort of individuals due to the intervention. In the selection of audio books, language fluency, spelling rules and accessibility were taken into consideration and audiobook platforms to which the researchers were members were used.
Study: NCT06343324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: Patients using noninvasive ventilation at home will receive detailed information about accessing, logging in and using web-based training. Pretest data will be collected, then week 4 and week 8 data will be collected.
Study: NCT04858711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-lidocaine-dexmedetomidine
Description: In the KLD group, patients will be administered 0,25 mcg/kg Dexmedetomidine in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of the solution containing ketamine, lidocaine and dexmedetomidine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: In the fentanyl group, patients will be administered 2 mcg/kg fentanyl in 100 mL of normal saline within 10 minutes. Followingly, they will receive 1mL/10 kg of normal saline solution 0.9%. As maintenance, they will be receiving 1mL/10kg/h of normal saline solution 0.9%.
Study: NCT05483647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltrative anaesthesia
Description: In prone position, before the skin incision, patients in G1 underwent local infiltrative anaesthesia et the level of incision. The skin, subcutaneous tissue and muscles up to the foramen intervertebral were anesthetized by the surgeon employing forty millilitre solution of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018%.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spine plane block
Description: The transverse vertebral process of the required level of spine was identified using the mobile C-arm X-ray System. When the tip of the 22G needle reached to the transverse vertebral process 3 cm lateral to the spinous process, a solution of 40 millilitres of Lidocaine 1% with Dexamethasone 0.02% and Epinephrine 0.00018% was injected under the erector spinae muscle bilaterally.
Study: NCT02716090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl peroxide Dalap Duo®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene and Benzoyl peroxide Epiduo®
Study: NCT05803317

Intervention type: OTHER
Intervention: usual care : Evaluation of walking on a baropodometric platform
Description: Pure observationnal study
Study: NCT05391438

Intervention type: OTHER
Group type: OTHER
Intervention: Meal-timing
Description: We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
Study: NCT06545227

Intervention type: DEVICE
Intervention: continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.
Description: To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
Study: NCT06279286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, placebo tablets matching the HS-10506 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, placebo tablets matching the HS-10506 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, placebo tablets matching the HS-10506 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, placebo tablets matching the HS-10506 tablets
Study: NCT06545227

Intervention type: OTHER
Intervention: Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)
Description: To study maternal metabolome

Intervention type: OTHER
Intervention: Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)
Description: To study maternal metabolome

Intervention type: OTHER
Intervention: Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)
Description: To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.

Intervention type: OTHER
Intervention: Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)
Description: To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.

Intervention type: OTHER
Intervention: Maternal and neonatal outcome data collection for all women in the study
Description: Data for maternal and neonatal outcomes will be collected

Intervention type: OTHER
Intervention: Maternal and neonatal outcome data collection for all women in the study
Description: Data for maternal and neonatal outcomes will be collected
Study: NCT04790383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Self-Adhesive resin composite hybrid restorations (Surefil one (Dentsply Sirona)).
Description: Hybrid resin composite that doesn't need bonding system and releases calcium and flouride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resin composite restoration. (Sphere Tec, (Dentsply Sirona
Description: Conventional Nanohybrid resin composite
Study: NCT05843227

Intervention type: OTHER
Intervention: questionnaire on the organizational management
Description: Data are collected through a questionnaire on the organizational management of the pre-operative / intraoperative / postoperative periods.